Research Article
Comparison of Urine and Cervical Samples for Genotyping Via HPV DNA Test
Issue:
Volume 9, Issue 3, September 2024
Pages:
36-43
Received:
4 September 2024
Accepted:
25 September 2024
Published:
18 October 2024
Abstract: Background: Human papillomavirus (HPV) is a key factor in cervical cancer development. This study aimed to compare the efficacy of urine and cervical samples for HPV genotyping, evaluating their diagnostic performance in detecting high-risk HPV genotypes. Methods: This comparative cross-sectional study conducted over one year at the Department of Gynaecological Oncology, BSMMU, Dhaka, the study enrolled 74 women aged 30-60 years with positive visual inspection with acetic acid (VIA) results or abnormal Pap test findings. Urine samples (20 ml) and cervical samples were collected from each participant. The samples were analyzed using multiplex real-time PCR to amplify high-risk HPV types (16, 18, and others). DNA was extracted using the Qiagen viral DNA extraction kit. Sensitivity and specificity of HPV detection in urine samples were compared to cervical sampling, the gold standard. Data were analyzed with SPSS 22.0, and agreement was assessed using the Kappa index. Result: Cervical samples detected HPV in 17.56% of participants, while urine samples identified HPV in 5.40%. The agreement between urine and cervical samples was moderate, with a kappa value of 0.743. Among 74 cases, 5 cases were detected as HPV 16 and HR (co-injection) in both cervical and urine sample, 2 cases as HPV 16 in both cervical and urine samples, 2 cases as only HR type in both cervical and urine sample. The kendall’s correlation of agreement was 0.361 and a significance of 0.002. Conclusion: Cervical samples are more reliable for HPV detection compared to urine samples, though urine testing shows high sensitivity.
Abstract: Background: Human papillomavirus (HPV) is a key factor in cervical cancer development. This study aimed to compare the efficacy of urine and cervical samples for HPV genotyping, evaluating their diagnostic performance in detecting high-risk HPV genotypes. Methods: This comparative cross-sectional study conducted over one year at the Department of G...
Show More
Commentary
CDA Formulations: Potentially the Standard Care of Breast, Lung and Liver Cancers
Issue:
Volume 9, Issue 3, September 2024
Pages:
44-51
Received:
16 October 2024
Accepted:
30 October 2024
Published:
28 November 2024
Abstract: Breast and lung cancers are very common, which are the top two leading causes of death from cancer. Hepatomas are not as common. But hepatomas are not responding well to therapies currently available. Cancer incidence and mortality keep on increasing ever since these statistics became public records, which are an indication of the failure of the health profession to control cancer. Cancer therapies approved in the past are mostly based on killing of cancer cells which are wrong to solve only a fraction of cancer problems. To effectively solve cancer, we must eliminate all factors contributing to the evolution of cancer. Cancer evolves due to wound unhealing because of the collapse of chemo-surveillance. Wound healing requires the proliferation and the terminal differentiation of progenitor stem cells (PSCs), which are embryonic stem cells to initiate the development of organs and tissues. Methylation enzymes (MEs) play a pivotal role on the regulation of cell replication and differentiation. Because of this pivotal role, MEs are exceptionally subjected to double allosteric regulations, on the individual enzymes by steroid hormone and on the enzyme complex by telomerase and chemo-surveillance. MEs of embryonic stem cells (ESCs) including PSCs are abnormal due to association with telomerase, which are important for the functions of these cells for the development of fetus and wound healing. The build-up of normal stem cells with abnormal MEs is strictly under regulations by contact inhibition, ten-eleven translocator -1 (TET-1) enzyme to direct lineage transitions and chemo-surveillance to destabilize abnormal MEs. When such safety mechanisms fail, clinical symptoms arise. Obviously, the most appropriate solution of diseases due to wound unhealing is to restore safety mechanisms created by the nature. Cell differentiation agent -2 (CDA-2) is our creation of cancer drug to target on abnormal MEs. CDA-2 was approved by the Chinese FDA as an adjuvant to supplement cytotoxic therapy of cancer against breast, non-small cell lung cancers and primary hepatomas in 2004, and as a mono-therapeutic agent for the therapy of myelodysplastic syndromes (MDSs) in 2017. MDSs are diseases attributable entirely to cancer stem cells (CSCs). CDA-2 was the best drug for the therapy of MDSs, and therefore should be considered the standard care of MDSs. Breast, non-small cell lung cancers and primary hepatomas responded well to CDA-2. The therapeutic end point of CDA-2 is the terminal differentiation of cancer cells which cannot make tumor to disappear. Evidently, terminal differentiation of CSCs is the only option to solve CSCs. The solution of CSCs is very critical to the success of cancer therapy. Therefore, CDA formulations are potentially the standard care of breast and lung cancers and primary hepatomas.
Abstract: Breast and lung cancers are very common, which are the top two leading causes of death from cancer. Hepatomas are not as common. But hepatomas are not responding well to therapies currently available. Cancer incidence and mortality keep on increasing ever since these statistics became public records, which are an indication of the failure of the he...
Show More
,
Rowson Ara
